Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
NVIV > SEC Filings for NVIV > Form 8-K on 21-Nov-2013All Recent SEC Filings

Show all filings for INVIVO THERAPEUTICS HOLDINGS CORP.

Form 8-K for INVIVO THERAPEUTICS HOLDINGS CORP.


21-Nov-2013

Regulation FD Disclosure


Item 7.01. Regulation FD Disclosure.

On November 21, 2013, InVivo Therapeutics Holdings Corp. (the "Company") submitted a filing to the FDA containing proposed changes to its FDA-approved protocol and supporting documents for its scaffold program to treat spinal cord injuries. An FDA guidance document provides that the agency will try to respond to such filings within thirty days. The Company believes that approval of the proposed changes would accelerate the progress of its clinical trial for the scaffold product by eliminating barriers to enrollment and by expanding the number of sites from at least three to as many as six.

Safe Harbor Statement

Any statements contained in this Form 8-K that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, and include statements regarding the Company's expectations with respect to the impact that the revised protocol would have on the progress of the clinical trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to obtain FDA approval of its revised protocol and the timing thereof; the identification of appropriate clinical sites; the Institutional Review Board process; the Company's ability to enter into partnerships; the Company's ability to obtain FDA approval to commercialize its products; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company's filings with the SEC, including the Company's Form 10-K and 10-Qs and its current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.


  Add NVIV to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NVIV - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.